Retrospective 10-year follow-up of 129 of 143 patients from the LIR!C trial in ileocaecal Crohn's disease: therapy-free remission was 35.8% after ileocaecal resection vs 13.2% with infliximab; overall clinical remission was similar (HR 0.79, non-significant).
RCTn = 129
Oldenburg et al. Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial